Following is a transcript of their remarks:
Hope Rugo, MD: Hello and welcome to this virtual roundtable where we will be discussing some of the key data that emerged from this year's San Antonio Breast Cancer meeting. I'm Hope Rugo, professor of medicine at the University of California San Francisco's Comprehensive Cancer Center, and I'm joined today by two expert leaders in the field of breast cancer and great colleagues, Dr. Jennifer Litton from the MD Anderson Cancer Center and Dr. Jo Chien from the University of California San Francisco's Comprehensive Cancer Center. Thanks for joining me today.
Now, we're going to talk about a really interesting set of presentations at San Antonio that I think really do have direct implications for clinical practice on Monday and this is the use of genomic tests -- and in some of the studies, Ki67 -- in order to try and inform us about how to treat our patients who have higher risk node-positive disease.